Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.

Jeongkuk SeoSeonok KimSeung Wook HongSung Wook HwangSang Hyoung ParkDong-Hoon YangSeung Wook HongSeung-Jae MyungSuk-Kyun YangYe-Jee KimByong Duk Ye

Published in: Alimentary pharmacology & therapeutics (2024)

In this nationwide population-based study, discontinuing 5-ASA after starting anti-TNF therapy was not associated with an increased risk of adverse events in patients with IBD.

Keyphrases

patients with inflammatory bowel disease
rheumatoid arthritis
cross sectional
mesenchymal stem cells